UNSPSC 51284013: Nitrocycline

This classification denotes a tetracycline antibiotic with the molecular formula C21H21N3O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2JH9LR1Y6S, chemically known as 4-(dimethylamino)-1,3,3a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-nitro-1,11-dioxo-2-naphthacene-carboxamide but generally known as nitrocycline, which bears US NIH Compound Identifier 5489904. European Medicines Agency schedules Nitrocycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09323MIG.

UNSPSC 51284013 Nitrocycline, a Commodity code, does not align with the state and local contract opportunities recently posted under this classification. The recent solicitations tagged to this code involve naloxone procurement, direct-to-manufacturer pharmacy initiatives, medical and first aid supplies for emergency response, and generic pharmaceuticals through cooperative purchasing — none of which concern nitrocycline specifically. The code shows little relevant recent activity; the mismatch between the code's nominal scope and the work actually being solicited suggests either a cataloging error in the state or local procurement system or that nitrocycline itself is not a material procurement driver in recent state and local contracting.

The opportunities appearing under this code reflect broader state and local purchasing patterns in emergency medical supplies and pharmaceutical distribution. Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023) targets annual procurement of 1,900 naloxone units and 800 deactivation systems with quarterly delivery; the City of Tampa's ITB for medical and first aid supplies (posted March 25, 2026, due March 13, 2026) encompasses 169 line items for the Fire Department Rescue Division with an estimated contract value of $700,000.00 and is sheltered for certified Small Local Business Enterprises with a 5 percent bid discount; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP (posted January 20, 2026, due March 26, 2026) seeks generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers. The Texas Health and Human Services Commission's RFI (posted April 3, 2026) gathered vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Procurement activity under this code reflects county health departments, municipal fire departments, state cooperative purchasing vehicles, and state health agencies across Florida, Texas, Minnesota, and Oregon.